Envista (NYSE:NVST) Stock Gets Price Target Boost from UBS Group

Envista (NYSE:NVST) had its price objective increased by UBS Group from $27.00 to $29.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s price target points to a potential upside of 15.09% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Leerink Partners decreased their target price on shares of Envista from $35.00 to $32.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Morgan Stanley set a $23.00 price target on Envista in a research report on Thursday, August 6th. Mizuho set a $29.00 price objective on Envista in a research note on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday. Six analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $29.00.

Envista Price Performance

Shares of NVST stock traded up $0.24 on Thursday, hitting $25.20. 3,234,799 shares of the stock traded hands, compared to its average volume of 2,950,992. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07. Envista has a 52 week low of $18.77 and a 52 week high of $30.42. The firm has a 50 day simple moving average of $24.38 and a two-hundred day simple moving average of $25.74. The firm has a market cap of $4.05 billion, a price-to-earnings ratio of 6.51, a PEG ratio of 1.26 and a beta of 0.94.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $691.50 million during the quarter, compared to analyst estimates of $688.74 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The company’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.32 EPS. As a group, equities research analysts predict that Envista will post 1.54 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the transaction, the senior vice president directly owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. The trade was a 22.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.99% of the company’s stock.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Diversified Trust Co purchased a new position in shares of Envista during the third quarter valued at approximately $755,000. AlphaCore Capital LLC bought a new stake in shares of Envista during the 3rd quarter worth approximately $330,000. Hohimer Wealth Management LLC lifted its stake in shares of Envista by 6.3% during the 3rd quarter. Hohimer Wealth Management LLC now owns 10,934 shares of the company’s stock worth $257,000 after acquiring an additional 651 shares during the last quarter. Brighton Jones LLC boosted its holdings in Envista by 36.0% during the 3rd quarter. Brighton Jones LLC now owns 20,908 shares of the company’s stock valued at $491,000 after acquiring an additional 5,540 shares during the period. Finally, CenterBook Partners LP boosted its holdings in Envista by 2.2% during the 3rd quarter. CenterBook Partners LP now owns 26,441 shares of the company’s stock valued at $621,000 after acquiring an additional 581 shares during the period.

Envista News Roundup

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q3 results topped expectations: Envista reported adjusted earnings of $0.40 per share and revenue of $691.5 million, both above analyst estimates. Revenue rose 3.2% year over year, while earnings increased from $0.32 a year earlier. Envista tops Q3 earnings and revenue estimates
• Positive Sentiment: 2026 outlook raised: Management lifted its earnings outlook, citing pricing and productivity gains—an encouraging signal for near-term profitability. Q3 earnings-call highlights
• Positive Sentiment: UBS raised its price target from $27 to $29, though it maintained a Neutral rating. UBS Group stock recommendations
• Neutral Sentiment: Some valuation commentary argues NVST may be undervalued following a substantial prior decline, while a Zacks article highlights its momentum score. These are analyst perspectives rather than new company developments. Envista could be undervalued on earnings guidance
• Negative Sentiment: China remains a forward-looking risk: Procurement reforms there could weigh on margins as Envista enters 2027, potentially offsetting some benefits from pricing and productivity improvements. Q3 earnings-call highlights

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.